193 related articles for article (PubMed ID: 27297359)
1. Recent advances in the development of sphingosine kinase inhibitors.
Pitman MR; Costabile M; Pitson SM
Cell Signal; 2016 Sep; 28(9):1349-1363. PubMed ID: 27297359
[TBL] [Abstract][Full Text] [Related]
2. Inhibitors of the sphingosine kinase pathway as potential therapeutics.
Pitman MR; Pitson SM
Curr Cancer Drug Targets; 2010 Jun; 10(4):354-67. PubMed ID: 20370685
[TBL] [Abstract][Full Text] [Related]
3. Roles, regulation and inhibitors of sphingosine kinase 2.
Neubauer HA; Pitson SM
FEBS J; 2013 Nov; 280(21):5317-36. PubMed ID: 23638983
[TBL] [Abstract][Full Text] [Related]
4. Sphingosine 1-phosphate and sphingosine kinases in health and disease: Recent advances.
Pyne S; Adams DR; Pyne NJ
Prog Lipid Res; 2016 Apr; 62():93-106. PubMed ID: 26970273
[TBL] [Abstract][Full Text] [Related]
5. A selective ATP-competitive sphingosine kinase inhibitor demonstrates anti-cancer properties.
Pitman MR; Powell JA; Coolen C; Moretti PA; Zebol JR; Pham DH; Finnie JW; Don AS; Ebert LM; Bonder CS; Gliddon BL; Pitson SM
Oncotarget; 2015 Mar; 6(9):7065-83. PubMed ID: 25788259
[TBL] [Abstract][Full Text] [Related]
6. Targeting the sphingosine kinase/sphingosine 1-phosphate pathway in disease: review of sphingosine kinase inhibitors.
Orr Gandy KA; Obeid LM
Biochim Biophys Acta; 2013 Jan; 1831(1):157-66. PubMed ID: 22801037
[TBL] [Abstract][Full Text] [Related]
7. Sphingosine kinase 1 as an anticancer therapeutic target.
Gao Y; Gao F; Chen K; Tian ML; Zhao DL
Drug Des Devel Ther; 2015; 9():3239-45. PubMed ID: 26150697
[TBL] [Abstract][Full Text] [Related]
8. Characterization of isoenzyme-selective inhibitors of human sphingosine kinases.
Gao P; Peterson YK; Smith RA; Smith CD
PLoS One; 2012; 7(9):e44543. PubMed ID: 22970244
[TBL] [Abstract][Full Text] [Related]
9. Sphingosine kinase/sphingosine 1-phosphate signaling in cancer therapeutics and drug resistance.
Selvam SP; Ogretmen B
Handb Exp Pharmacol; 2013; (216):3-27. PubMed ID: 23563649
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of sphingosine kinase inhibitors.
French KJ; Upson JJ; Keller SN; Zhuang Y; Yun JK; Smith CD
J Pharmacol Exp Ther; 2006 Aug; 318(2):596-603. PubMed ID: 16632640
[TBL] [Abstract][Full Text] [Related]
11. Structure-function analysis of lipid substrates and inhibitors of sphingosine kinases.
Adams DR; Pyne S; Pyne NJ
Cell Signal; 2020 Dec; 76():109806. PubMed ID: 33035646
[TBL] [Abstract][Full Text] [Related]
12. Sphingosine kinase 1 in cancer.
Heffernan-Stroud LA; Obeid LM
Adv Cancer Res; 2013; 117():201-35. PubMed ID: 23290781
[TBL] [Abstract][Full Text] [Related]
13. Expression of a catalytically inactive sphingosine kinase mutant blocks agonist-induced sphingosine kinase activation. A dominant-negative sphingosine kinase.
Pitson SM; Moretti PA; Zebol JR; Xia P; Gamble JR; Vadas MA; D'Andrea RJ; Wattenberg BW
J Biol Chem; 2000 Oct; 275(43):33945-50. PubMed ID: 10944534
[TBL] [Abstract][Full Text] [Related]
14. Increased sphingosine 1-phosphate mediates inflammation and fibrosis in tubular injury in diabetic nephropathy.
Yaghobian D; Don AS; Yaghobian S; Chen X; Pollock CA; Saad S
Clin Exp Pharmacol Physiol; 2016 Jan; 43(1):56-66. PubMed ID: 26414003
[TBL] [Abstract][Full Text] [Related]
15. Sphingosine kinase 1 as a potential therapeutic target in epithelial ovarian cancer.
Lee JW; Ryu JY; Yoon G; Jeon HK; Cho YJ; Choi JJ; Song SY; Do IG; Lee YY; Kim TJ; Choi CH; Kim BG; Bae DS
Int J Cancer; 2015 Jul; 137(1):221-9. PubMed ID: 25429856
[TBL] [Abstract][Full Text] [Related]
16. A selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemia.
Paugh SW; Paugh BS; Rahmani M; Kapitonov D; Almenara JA; Kordula T; Milstien S; Adams JK; Zipkin RE; Grant S; Spiegel S
Blood; 2008 Aug; 112(4):1382-91. PubMed ID: 18511810
[TBL] [Abstract][Full Text] [Related]
17. Development of small-molecule inhibitors of sphingosine-1-phosphate signaling.
Edmonds Y; Milstien S; Spiegel S
Pharmacol Ther; 2011 Dec; 132(3):352-60. PubMed ID: 21906625
[TBL] [Abstract][Full Text] [Related]
18. Eukaryotic elongation factor 1A interacts with sphingosine kinase and directly enhances its catalytic activity.
Leclercq TM; Moretti PA; Vadas MA; Pitson SM
J Biol Chem; 2008 Apr; 283(15):9606-14. PubMed ID: 18263879
[TBL] [Abstract][Full Text] [Related]
19. Short Periods of Hypoxia Upregulate Sphingosine Kinase 1 and Increase Vasodilation of Arteries to Sphingosine 1-Phosphate (S1P) via S1P
Alganga H; Almabrouk TAM; Katwan OJ; Daly CJ; Pyne S; Pyne NJ; Kennedy S
J Pharmacol Exp Ther; 2019 Oct; 371(1):63-74. PubMed ID: 31371480
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and evaluation of sphingosine analogues as inhibitors of sphingosine kinases.
Wong L; Tan SS; Lam Y; Melendez AJ
J Med Chem; 2009 Jun; 52(12):3618-26. PubMed ID: 19469544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
